Sector pending / Drugs, Drug Proprietaries, and Druggists' SundriesUpdated 2026-05-10 22:07 UTC

FRA/X2S1 stock hub

FRA/X2S1 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/X2S1is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

6.2B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/X2S1

In the news

Latest news · FRA/X2S1

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E6.3

P25 n/aP50 n/aP75 n/a

Trailing P/E7

P25 n/aP50 n/aP75 n/a

ROE8.1

P25 n/aP50 n/aP75 n/a

ROIC7.6

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/X2S1 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

210

Groups with data

Currency

CNY

Showing 210 of 210 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	China
Country code	DE
Employees	94,910
Employees Change	-7,742%
Employees Change Percent	-6.68
Enterprise value	EUR 17.4B
Exchange	Frankfurt Stock Exchange
Financial currency	CNY
First seen	2026-05-10
Industry	Drugs, Drug Proprietaries, and Druggists' Sundries
Last refreshed	2026-05-10
Market cap	EUR 6.2B
Price	EUR 10
Price currency	EUR
Rev Per Employee	760,833.58x
Sic	5122
Symbol	fra/X2S1
Website	https://www.sinopharmgroup.com.cn

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	14.33%
EV Earnings	19.44x
EV/EBIT	7.67x
EV/EBITDA	6.29x
EV/FCF	9.4x
EV/Sales	0.25x
FCF yield	29.65%
Forward P/E	6.28x
P/B ratio	0.36x
P/E ratio	6.98x
P/S ratio	0.09x
PE Ratio10 Y	10.23x
PE Ratio3 Y	7.43x
PE Ratio5 Y	7.03x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	2.98%
EBITDA Margin	3.33%
FCF margin	2.56%
Gross margin	7.17%
Gross Profit	EUR 5.2B
Gross Profit Growth	-5.53%
Gross Profit Growth Q	-5.25%
Gross Profit Growth3 Y	-5.24%
Gross Profit Growth5 Y	0.11%
Net Income	EUR 894.3M
Net Income Growth	0.36%
Net Income Growth Q	-2.95%
Net Income Growth3 Y	-6.45%
Net Income Growth5 Y	0.45%
Pretax Margin	2.57%
Profit Margin	1.24%
Profit Per Employee	EUR 9,423
ROA	2.63
Roa5y	3.49
ROCE	11.73
ROE	8.11
Roe5y	11.45
ROIC	7.59
Roic5y	12.13

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-0.04%
Cagr3y	-10.97%
Cagr5y	-3.45%
Div CAGR3	-10.74%
EPS Growth	-0
EPS Growth Q	-4.26
EPS Growth3 Y	-6.56
EPS Growth5 Y	0.32
FCF Growth	-37.2%
FCF Growth3 Y	0.96%
OCF Growth	-34.37%
OCF Growth3 Y	-1.04%
Revenue Growth	-0.8x
Revenue Growth Q	-0.63x
Revenue Growth3 Y	0.25x
Revenue Growth5 Y	3.88x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 1.41
Assets	EUR 50.4B
Cash	EUR 4.6B
Current Assets	EUR 44.4B
Current Liabilities	EUR 31.8B
Debt	EUR 9.5B
Debt EBITDA	EUR 3.58
Debt Equity	EUR 0.56
Debt FCF	EUR 5.15
Equity	EUR 17.2B
Interest Coverage	7.69
Liabilities	EUR 33.2B
Long Term Assets	EUR 6B
Long Term Liabilities	EUR 1.5B
Net Cash	EUR -5B
Net Cash By Market Cap	EUR -79.35
Net Debt EBITDA	EUR 2.06
Net Debt Equity	EUR 0.29
Net Debt FCF	EUR 2.68
Tangible Book Value	EUR 9.6B
Tangible Book Value Per Share	EUR 3.06

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.4
Inventory Turnover	8.03
Net Working Capital	EUR 16.9B
Quick ratio	1.1
Working Capital	EUR 12.7B
Working Capital Turnover	EUR 0.74

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.24%
Dividend Growth	-34.87%
Dividend Growth Years	0%
Dividend per share	EUR 0.3
Dividend Years	6
Dividend Yield	3.04%
Ex Div Date	2025-06-17
Last Dividend	EUR 0.3
Payout Frequency	Annual
Payout Ratio	28.21%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-0.04%
200-day SMA	10.8
3Y total return	-29.43%
50-day SMA	11.09
50-day SMA vs 200-day SMA	50over200
5Y total return	-16.12%
All Time High	15.9
All Time High Change	-37.11%
All Time High Date	2023-04-27
All Time Low	8.61
All Time Low Change	16.17%
All Time Low Date	2022-02-22
ATR	0.12
Ch YTD	-5.66
High	10
High52	11.8
High52 Date	2026-03-17
High52ch	-15.25%
Low	10
Low52	9.8
Low52 Date	2025-10-01
Low52ch	2.04%
Ma50ch	-9.81%
Price vs 200-day SMA	-7.36%
RSI	28.68
RSI Monthly	43.54
RSI Weekly	36.37
Sharpe ratio	-0.13x
Sortino ratio	0.08
Total Return	2.81%
Tr YTD	-5.66
Tr1m	-13.04%
Tr1w	-0.99%
Tr3m	-12.28%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 2.2B
Operating Income Growth	-2.64
Operating Income Growth Q	-2.96
Operating Income Growth3 Y	-9.37
Operating Income Growth5 Y	-1.55
Operating margin	2.98

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,341,810,740%
Net Borrowing	-2,310,277,186.1
Shares Institutions	29.1%
Shares Qo Q	0.8%
Shares Yo Y	0.24%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 1.9B
Average Volume	0x
Bv Per Share	3.45
CAPEX	EUR -192.3M
Ch1m	-13.04
Ch1w	-0.99
Ch1y	-2.91
Ch3m	-12.28
Ch3y	-35.9
Ch5y	-28.67
Ch6m	-8.26
Change	-0.99%
Change From Open	0
Close	10.1
Days Gap	-0.99
Depreciation Amortization	249,978,157.7
Earnings Date	2026-04-24
EBIT	EUR 2.2B
EBITDA	EUR 2.4B
EPS	EUR 0.29
F Score	6
FCF	EUR 1.9B
FCF EV Yield	10.64x
Financing CF	-2,985,773,284
Fiscal Year End	December
Founded	2,003
Goodwill	715,071,131.7
Graham Number	29.77289
Graham Upside	197.7
Income Tax	EUR 501.6M
Investing CF	-243,353,085
Is Primary Listing	0
Last Earnings Date	2026-04-24
Last Report Date	2026-03-31
Lynch Fair Value	EUR 7.16
Lynch Upside	-28.36
Ma150	11
Ma150ch	-9.07%
Ma20	10.62
Ma20ch	-5.79%
Net CF	-1,187,784,088
Next Earnings Date	2026-08-28
Open	10
P FCF Ratio	3.37
P OCF Ratio	3.06
Payment Date	2025-08-27
Ppne	1,883,387,127.8
Price Date	2026-05-08
Price EBITDA	EUR 2.59
Ptbv Ratio	0.65
Relative Volume	2,000x
Revenue	72,210,714,716x
Tax By Revenue	0.69x
Tax Rate	27.04%
Tr6m	-8.26%
Z Score	2.22

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

FRA/X2S1 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+3.0%

$0.30 annual per share

Payout ratio

+28.2%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

0 consecutive years of growth

Total shareholder yield

+2.8%

Next ex-dividend date: 2025-06-17

Performance

FRA/X2S1 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/X2S1?

Insider, institutional, and short-interest positioning.

Institutional ownership

+29.1%

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.2%

Negative means the company is buying back shares.

Technical

FRA/X2S1 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

28.7

Below 30: short-term oversold

Price vs 200-day MA

-7.4%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.13

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/X2S1

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/X2S1 stock rating?

fra/X2S1 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/X2S1 analysis?

The full report lives at /stocks/fra/X2S1/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/X2S1?

The latest report frames fra/X2S1 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/X2S1 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.